A Rapid and Sensitive UPLC-MS/MS Method for the Determination of Bellidifolin and Pharmacokinetics Study of Bellidifolin Nano-microcells

IF 0.7 4区 医学 Q4 PHARMACOLOGY & PHARMACY Current Pharmaceutical Analysis Pub Date : 2023-10-20 DOI:10.2174/0115734129253094231018115646
Jiaye Tian, Ran Bai, Ziyue Chen, Piaoran Qin, Xingchao Liu, Haoran Shen, Li Zhou, Qiuhong Guo
{"title":"A Rapid and Sensitive UPLC-MS/MS Method for the Determination of Bellidifolin and Pharmacokinetics Study of Bellidifolin Nano-microcells","authors":"Jiaye Tian, Ran Bai, Ziyue Chen, Piaoran Qin, Xingchao Liu, Haoran Shen, Li Zhou, Qiuhong Guo","doi":"10.2174/0115734129253094231018115646","DOIUrl":null,"url":null,"abstract":"Background:: Bellidifolin (BEL) has a decent enemy of myocardial fibrosis impact, and its preparation into nano-micelles can build security and great biocompatibility in vitro and in vivo. The pharmacokinetic assessment of BEL can be utilized as the reason for the security and viability of BEL in clinical use. Objective:: This research aimed to establish an effective UPLC-MS/MS strategy for assuring BEL in rodent plasma and concentrating on its pharmacokinetics in vivo. objective: This research aimed to establish an effective UPLC-MS/MS strategy for assuring BEL in rodent plasma and concentrating on its pharmacokinetics in vivo. Methods:: Luteolin was utilized as an internal standard (IS). Chromatographic separation was accomplished utilizing a UPLC HSS T3 column (2.1 ×100 mm, 1.8 μm) section using a mobile phase of 0.1% acetonitrile (A) and 0.1% formic acid in water (B) with gradient elution. Electrospray ionization (ESI) coupled mass spectrometry was applied in various response checking (MRM) modes with negative ionization. Results:: The pharmacokinetic behaviour of bellidifolin nano-micelles in vivo showed that the peak concentration (Cmax) was 1666.19±479.92 μg/L, the time to peak (Tmax) was 0.167 h, and the apparent elimination half-life (t1/2) was 7.60±3.58 h. The plasma clearance rate (CL/F) was 1.15±0.48 L/h/kg, the apparent volume of distribution (V/F) was 14.38±11.04, the area under the curve (AUC) was 8292.57±4193.13 μg/L*h, and the mean retention time (MRT) was 9.70±4.55 h. Conclusion:: The method was successfully applied to the plasma pharmacokinetics of bellidifolin nano-micelles after intragastric administration to rats. other: None.","PeriodicalId":10889,"journal":{"name":"Current Pharmaceutical Analysis","volume":"1 1","pages":"0"},"PeriodicalIF":0.7000,"publicationDate":"2023-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Pharmaceutical Analysis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115734129253094231018115646","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background:: Bellidifolin (BEL) has a decent enemy of myocardial fibrosis impact, and its preparation into nano-micelles can build security and great biocompatibility in vitro and in vivo. The pharmacokinetic assessment of BEL can be utilized as the reason for the security and viability of BEL in clinical use. Objective:: This research aimed to establish an effective UPLC-MS/MS strategy for assuring BEL in rodent plasma and concentrating on its pharmacokinetics in vivo. objective: This research aimed to establish an effective UPLC-MS/MS strategy for assuring BEL in rodent plasma and concentrating on its pharmacokinetics in vivo. Methods:: Luteolin was utilized as an internal standard (IS). Chromatographic separation was accomplished utilizing a UPLC HSS T3 column (2.1 ×100 mm, 1.8 μm) section using a mobile phase of 0.1% acetonitrile (A) and 0.1% formic acid in water (B) with gradient elution. Electrospray ionization (ESI) coupled mass spectrometry was applied in various response checking (MRM) modes with negative ionization. Results:: The pharmacokinetic behaviour of bellidifolin nano-micelles in vivo showed that the peak concentration (Cmax) was 1666.19±479.92 μg/L, the time to peak (Tmax) was 0.167 h, and the apparent elimination half-life (t1/2) was 7.60±3.58 h. The plasma clearance rate (CL/F) was 1.15±0.48 L/h/kg, the apparent volume of distribution (V/F) was 14.38±11.04, the area under the curve (AUC) was 8292.57±4193.13 μg/L*h, and the mean retention time (MRT) was 9.70±4.55 h. Conclusion:: The method was successfully applied to the plasma pharmacokinetics of bellidifolin nano-micelles after intragastric administration to rats. other: None.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
快速、灵敏的超高效液相色谱-串联质谱/串联质谱法测定贝利迪福林及纳米微细胞药动学研究
背景:贝利迪福林(Bellidifolin, BEL)具有良好的抗心肌纤维化作用,其纳米胶束制备在体外和体内均具有良好的安全性和生物相容性。BEL的药代动力学评价可作为BEL临床应用安全性和可行性的依据。目的:建立一种有效的UPLC-MS/MS策略,以确保啮齿动物血浆中BEL的含量,并集中研究其体内药代动力学。目的:建立一种有效的UPLC-MS/MS策略,以确保啮齿动物血浆中BEL的含量,并集中研究其体内药代动力学。方法:以木犀草素为内标。色谱分离采用UPLC HSS T3柱(2.1 ×100 mm, 1.8 μm),流动相为0.1%乙腈(a)和0.1%甲酸水溶液(B),梯度洗脱。将电喷雾电离(ESI)耦合质谱法应用于各种负电离响应检验(MRM)模式。结果:belllidifolin纳米胶束在体内的药代动力学行为表明,其峰浓度(Cmax)为1666.19±479.92 μg/L,峰时间(Tmax)为0.167 h,表观消除半衰期(t1/2)为7.60±3.58 h,血浆清除率(CL/F)为1.15±0.48 L/h/kg,表观分布容积(V/F)为14.38±11.04,曲线下面积(AUC)为8292.57±4193.13 μg/L*h,平均滞留时间(MRT)为9.70±4.55 h。该方法成功地应用于大鼠灌胃后贝利二福林纳米胶束的血浆药动学研究。其他:没有。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.50
自引率
0.00%
发文量
85
审稿时长
3 months
期刊介绍: Aims & Scope Current Pharmaceutical Analysis publishes expert reviews and original research articles on all the most recent advances in pharmaceutical and biomedical analysis. All aspects of the field are represented including drug analysis, analytical methodology and instrumentation. The journal is essential to all involved in pharmaceutical, biochemical and clinical analysis.
期刊最新文献
Simultaneous Estimation of Pregabalin and Duloxetine Used to Treat Nerve Pain by Stability Indicating RP-HPLC Method Using the QBD Approach Research on Compatibility of Packaging Materials of High-Risk Cephalosporin Powder Injection and Establishment of Indicator Component Evaluation Method Universally Applicable Methods for Comprehensive Risk Assessment of Elemental Impurities in Vitamin A and D Preparations An Overview of Biotechnological Drug’s Various Techniques of Downstream Process, Guideline’s And Different Chromatographic Analysis Validation of GF-AAS Method for the Determination of Aluminium Content in Human Albumin Finished Product
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1